Search

Original citation: J Clin Invest. 2023;133(3):1-19. https://doi.org/10.n72/JCI157272. Citation for this corrigendum: J Clin Invest. 2023;133(9):171350. https://doi.org/10.1172/JCI171350. Yen-Po Tsao, [1,2,3] Fang-Yu Tseng, [4] Chih-Wei Chao, [1,4] Ming-Han Chen, [2] Yi-Chen Yeh, [...]

Signaling driven by nucleic acid sensors participates in interferonopathy-mediated autoimmune diseases. NLRP12, a pyrin-containing NLR protein, is a negative regulator of innate immune activation and type I interferon (IFN-I) production. Peripheral blood mononuclear cells (PBMCs) derived from systemic lupus erythematosus (SLE) patients expressed lower levels of NLRP12, with an inverse correlation with IFNA expression and high disease activity. NLRP12 expression was transcriptionally suppressed by runt-related transcription factor 1-dependent (RUNX1-dependent) epigenetic regulation under IFN-I treatment, which enhanced a negative feedback loop between low NLRP12 expression and IFN-I production. Reduced NLRP12 protein levels in SLE monocytes was linked to spontaneous activation of innate immune signaling and hyperresponsiveness to nucleic acid stimulations. Pristane-treated [Nlrp12.sup.-/-] mice exhibited augmented inflammation and immune responses; and substantial lymphoid hypertrophy was characterized in NLRP12deficient lupus-prone mice. NLRP12 deficiency mediated the increase of autoantibody production, intensive glomerular IgG deposition, monocyte recruitment, and the deterioration of kidney function. These were bound in an IFN-I signature- dependent manner in the mouse models. Collectively, we reveal a remarkable link between low NLRP12 expression and lupus progression, which suggests the impact of NLRP12 on homeostasis and immune resilience., Introduction Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease with unknown etiology involving immune intolerance of endogenous nuclear materials, increased levels of auto-reactive B cells, and chronic inflammation, leading [...]